Amelioration of Muscle and Nerve Pathology in LAMA2 Muscular Dystrophy by AAV9-Mini-Agrin
Authors:
Open Access
- 1 June 2018
- journal article
- research article
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 9, 47-56
Abstract
No abstract availableKeywords
Funding Information
- NICHD (U54HD079124)
- NIH/NINDS (1RO1 NS079568)
This publication has 50 references indexed in Scilit:
- Comprehensive Mutation Analysis for Congenital Muscular Dystrophy: A Clinical PCR-Based Enrichment and Next-Generation Sequencing PanelPLOS ONE, 2013
- Angiotensin II type 1 receptor antagonists alleviate muscle pathology in the mouse model for laminin-α2-deficient congenital muscular dystrophy (MDC1A)Skeletal Muscle, 2012
- Peripheral nerve pathology, including aberrant Schwann cell differentiation, is ameliorated by doxycycline in a laminin- 2-deficient mouse model of congenital muscular dystrophyHuman Molecular Genetics, 2011
- Skeletal muscle laminin and MDC1A: pathogenesis and treatment strategiesSkeletal Muscle, 2011
- Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liverGene Therapy, 2010
- Basement Membranes: Cell Scaffoldings and Signaling PlatformsCold Spring Harbor Perspectives in Biology, 2010
- Pathology is alleviated by doxycycline in a laminin‐α2–null model of congenital muscular dystrophyAnnals of Neurology, 2009
- The zebrafishcandyflossmutant implicates extracellular matrix adhesion failure in laminin α2-deficient congenital muscular dystrophyProceedings of the National Academy of Sciences, 2007
- Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8Molecular Therapy, 2006
- An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophyNature, 2001